IQVIA Holdings Inc (IQV)

How it makes money

Three ways of getting paid sit side by side. The clinical research business is project work: multi-year trial contracts, billed as milestones and units of work are delivered, which build up a contracted backlog — $32.7 billion at the end of 2025, of which the company expects roughly $8.3 billion to convert into revenue over the following twelve months. That backlog is the closest thing IQVIA has to visibility, but the 10-K is explicit that most contracts can be cancelled on short notice, so it is an order book and not a guarantee. The data and analytics business is closer to a subscription: recurring licences to information offerings and cloud/SaaS platforms, renewed periodically, plus discrete consulting and analytics engagements. The contract sales and medical business is staffing-like — clients pay for sales, nurse and medical-education teams that IQVIA employs and deploys on their behalf. The economics differ sharply: data and software carry higher margins than the labour-intensive trial and field-team work.

Revenue by segment

The durable asset is the data estate, not the services. IQVIA has spent decades assembling licences with pharmacies, distributors, hospitals and other suppliers, and the resulting market-measurement and real-world datasets — roughly 1.2 billion non-identified patient records per the 2025 10-K — are the reference currency for how drug sales and treatment patterns are counted in many markets. A newcomer cannot buy that history, and clients who have built forecasting, incentive-compensation and regulatory submissions on top of it do not switch lightly. But this covers only the smaller of the two businesses. The clinical research side, which is the majority of revenue, competes for individual trials against other large CROs and against pharma companies keeping work in-house; it wins on scale, therapeutic track record and the ability to use its own patient data to find trial sites, not on any structural lock-in. One notable vulnerability sits inside the moat itself: the company's own risk factors flag that data suppliers can restrict how IQVIA uses their data or refuse to license it — the raw material is rented, not owned.

Drug development spending is not consumer spending: a phase III trial already under way is rarely cancelled because the economy turned, and the data licences renew whether or not it is a good year. That gives the revenue a defensive core. The cycle enters from two other doors. The first is biotech funding — small and mid-sized developers, who have no revenue of their own, commission trials out of money raised on capital markets, so when that window closes their bookings and cancellations move quickly, and the company itself lists credit and capital market disruption among its risks. The second is the large pharmaceutical customers' own patent and pipeline cycle: outsourced work follows where their R&D budgets go, and a wave of expiries or a strategic reset in a big client shows up as delayed decisions rather than an immediate revenue drop. The 2025 numbers show what this looks like in practice — the group grew 5.9% with the data and analytics side (up 7.6%) running ahead of clinical research (up 4.3%).

Key risks

• Most contracts can be cancelled on short notice — The company discloses that most of its contracts may be terminated on short notice, and that it may lose, or suffer delays on, large client contracts. A clinical trial that is stopped for scientific, regulatory or funding reasons takes its remaining backlog with it, so the reported order book can shrink without any loss of competitive position.
• Data suppliers can restrict or withdraw their data — Among its risk factors the company lists the imposition of restrictions on its use of data by data suppliers, or their refusal to license data to it. Because the information business is assembled from third-party sources rather than generated internally, a change of policy by large suppliers would strike directly at the product.
• Data protection and privacy law — The company flags any failure to comply with contractual, regulatory or ethical requirements under its contracts, including current or future changes to data protection and privacy laws. It handles patient-level health information across more than 100 jurisdictions, each of which can tighten the rules on what may be collected, combined or re-identified.
• Security breaches and system failures — Disclosed risks include breaches or misuse of the company's own security and communications systems or those of its outsourcing partners. A serious incident would hit both the trust that underpins the data licences and the clinical trial operations that run on those systems.
• The market may not grow as expected — The company states that the market for its services may not grow as it expects, that it may be unable to develop and market new services successfully or to enter new markets. Demand rests on pharmaceutical R&D and commercial budgets continuing to be outsourced at the rate assumed.
• Credit markets and economic conditions — The company discloses that disruptions in the credit and capital markets, together with unfavourable economic conditions, could hurt its business. This cuts two ways: it carried net debt of $13.744 billion at 3.63x trailing adjusted EBITDA at the end of 2025, and a large part of its client base — emerging biotech — funds its trials from those same capital markets.
• Global operations, currency and acquisitions — Risks disclosed include operating across many countries with the resulting currency exposure, business disruption from natural disasters, pandemics or international conflict, and the difficulty of integrating acquired businesses. Reported growth in 2025 was higher than constant-currency growth in every segment, which shows how much the top line moves with exchange rates.

Top customers account for 5% of revenue

Concentration is low for a business of this type. The 10-K states that no single client accounted for 10% or more of total company revenues in 2025, 2024 or 2023, and that the largest client represented approximately 5% of total revenues in 2025. The company reports over 10,000 clients and says it serves nearly all of the top 100 global pharmaceutical and biotechnology companies. The figure above is the largest single client, not a top-ten total, which the filing does not give. The concentration that matters here is of a different kind: the customer base is one industry, so a downturn in pharmaceutical R&D budgets reaches every account at once even though no single account is large.